Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Trial Profile

A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sargramostim (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Pharmacodynamics
  • Sponsors Sanofi

Most Recent Events

  • 05 Apr 2017 Planned End Date changed from 1 Apr 2018 to 31 Mar 2017.
  • 05 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 31 Mar 2017.
  • 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment due to slow recruitment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top